DataCitemetadata only

Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study

Name: Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study
License: Open Access

Tang, Honghu et al.

DataCite · Datasets · License: Open Access

Open Source ↗

ecology physiology

physiology, fos: biological sciences, pharmacology, environmental sciences not elsewhere classified, ecology, immunology

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 124886
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.